[Admin]

Since Retatrutide is still investigational and not commercially available, “switching” mostly comes up in the context of clinical trial interest or research curiosity rather than an actual real-world transition today. This thread is for discussing that interest — reasons, expectations, and how the compounds compare on paper.

Why members are interested

People researching Retatrutide after using semaglutide or tirzepatide are often drawn to the added glucagon-receptor mechanism and the larger average weight-loss figures reported in Retatrutide’s own trials (see the FAQ and vs. Tirzepatide threads for the actual numbers and their caveats).

Setting expectations

A few things worth keeping in mind:

• Retatrutide is not FDA-approved and is not available by prescription — access today is limited to clinical trial enrollment.
• There is no published head-to-head trial yet showing what actually happens when someone transitions between these specific compounds (the ongoing NCT06662383 trial compares treatment-naive groups, not a switch-over population).
• Public trial timelines suggest a possible FDA filing in late 2026, but approval and commercial availability — if they happen — are still a ways off.

Research comparisons

See the pinned FAQ thread and the Retatrutide vs. Tirzepatide thread for sourced trial data on how the three compounds compare mechanistically and in their respective trials.

This thread is for discussing research interest and publicly available trial information — not for protocol, dosing, or transition recommendations. Any real switch between therapies should be discussed with a licensed healthcare provider or, in the case of an actual trial, your study team.

[Author]

Posts